NCT06713369 - AZD5305 hADME in Patients With Advanced Solid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 2, 2025

Primary Completion Date

October 2, 2026

Study Completion Date

October 2, 2026

Conditions

Locally Advanced or Metastatic Solid Tumor

Interventions

DRUG

Saruparib (AZD5305)

PARP-inhibitor

DRUG

[14C]-AZD5305 microtracer

IV radiolabeled microtracer

DRUG

[14C]-AZD5305 (therapeutic dose)

IV radiolabeled PARP inhibitor

Trial Locations (2)

RECRUITING

Research Site, Liverpool

RECRUITING

Research Site, Manchester